Orlistat (fat absorption blocker) acutely increased appetite and reduced postprandial GLP-1 responses, proving that fat must be absorbed (not just present) to trigger satiety hormones — the gut needs to process fat to signal fullness.
Key findingOrlistat inhibition of intestinal lipase acutely increased appetite and attenuated GLP-1/PYY satiety responses, proving that fat absorption (not just
What the researchers found
Orlistat inhibition of intestinal lipase acutely increased appetite and attenuated GLP-1/PYY satiety responses, proving that fat absorption (not just fat presence) is required for satiety hormone release — the gut must PROCESS fat to signal fullness.
Why it matters
Relevant for glp-1, neuropeptides, weight-loss.
How the study worked
RCT study.
What this study cannot tell us
See abstract.
How to read the evidence
strong evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
The Journal of clinical endocrinology and metabolism, 93(10), 3995-8
Citation
Ellrichmann, Mark; Kapelle, Mario; Ritter, Peter R; Holst, Jens J; Herzig, Karl-Heinz; Schmidt, Wolfgang E; Schmitz, Frank; Meier, Juris J. (2008). Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.. The Journal of clinical endocrinology and metabolism, 93(10), 3995-8. https://doi.org/10.1210/jc.2008-0924